Company Overview
Snapshot
Founded in January 2023, ReadeRx Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing novel cancer treatments.
Business overview
ReadeRx Therapeutics is a Health Tech & Life Sciences company specializing in RNA-based cancer therapeutics. The company develops small molecule inhibitors that target the RNA binding protein IGF2BP1, which plays a pivotal role in stabilizing pro-oncogenic RNAs in various cancer types. By inhibiting IGF2BP1, ReadeRx aims to offer a novel treatment strategy for cancer, serving the pharmaceutical and healthcare industries.
Log in to access full profile ›Company Intelligence Q&A
- What is ReadeRx Therapeutics' primary focus?
- ReadeRx Therapeutics is focused on developing RNA-based cancer therapeutics, specifically targeting the RNA binding protein IGF2BP1 with small molecule inhibitors.
- When was ReadeRx Therapeutics founded?
- ReadeRx Therapeutics was founded in January 2023.
- What is the current employee size of ReadeRx Therapeutics?
- ReadeRx Therapeutics currently has 1–10 employees.
- What is the strategic importance of IGF2BP1 in cancer therapy?
- IGF2BP1 is an oncofetal RNA binding protein that is widely expressed during development but significantly reduced in normal mature tissues. In many cancers, it is reactivated and plays a crucial role in stabilizing pro-oncogenic RNAs, promoting tumor growth. Inhibiting IGF2BP1 is therefore considered a highly promising strategy for cancer therapy.
- What stage is ReadeRx Therapeutics currently in?
- ReadeRx Therapeutics is currently in the Pre-Funding stage, with its product in the R&D phase.